Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Interim report: No activity of isoniazid in the continuation phase

International Journal of Tuberculosis and Lung Disease

Volumn 4, Issue 3, 2000, Pages 262-267

  Tam, C M ^a   Chan, S L ^a   Kam, K M ^b   Sim, E ^c   Staples, D ^c   Sole, K M ^d   Al Ghusein, H ^d   Mitchison, D A ^d  

^a Wanchai Polyclinic   (Hong Kong)

^b Yung Fung Shee Memorial Centre   (Hong Kong)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Acetylation genotyping; Isoniazid; RFLP; Rifapentine; Tuberculosis

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; DRUG MIXTURE; DRUG RESPONSE; FOLLOW UP; HONG KONG; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ACETYLATION; ANTITUBERCULAR AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; DRUG THERAPY, COMBINATION; GENOTYPE; HONG KONG; HUMANS; ISONIAZID; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RIFAMPIN; TUBERCULOSIS, PULMONARY;

EID: 0034021783     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Tam C M, Chan S L, Lam C W, et al. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis: initial report. Am J Respir Crit Care Med 1998; 157: 1726-1733.
2. Mitchison D A, Ellard G A, Grosser J. New antibacterial drugs for the treatment of mycobacterial disease in man. Brit Med Bull 1988; 44: 757-774.
3. Mitchison D A. Development of rifapentine: the way ahead. Int J Tuberc Lung Dis 1998; 2: 612-615.
4. Chan S L, Yew W W, Porter J H D, et al. Comparison of Chinese and Western rifapenrines and improvement in bioavailability by prior taking of various meals. Int J Antimicrob Agents 1994; 3: 267-274.
5. Tam C M, Chan S L, Lam C W, Dickinson J M, Mitchison D A. Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong. Int J Tuberc Lung Dis 1997; 1: 411-416.
6. Keung A, Reith K, Eller M G, McKenzie K A, Cheng L, Weir S J. Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steady-state rifapentine pharmacokinetics: Part I. lnt J Tuberc Lung Dis 1999; 3: 426-436.
7. Van Embden J D A, Crawford J T, Dale J W, et al. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 1993; 31: 406-409.
8. Lin H J, Han C-Y, Lin B K, Hardy S. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, Blacks, Hispanics, and Whites: application to metabolic epidemiology. Am J Hum Genet 1993; 52: 827-834.
9. Risch A, Wallace D M A, Bathers S, Sim E. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Human Molecular Genetics 1995; 4: 231-236.
10. Vatsis K P, Martell K J, Weber W W. Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proc Natl Acad Sci USA 1991; 88: 6333-6337.
11. Das S, Chan S L, Allen B W, Mitchison D A, Lowrie D B. Application of DNA fingerprinting with JS986 to sequential mycobacterial isolates obtained from pulmonary tuberculosis patients in Hong Kong before, during and after short-course chemotherapy. Tubercle Lung Dis 1993; 74: 47-51.
12. Ellard G A, Gammon P T. Acetylator phenotyping of tuberculosis patients using matrix isoniazid or sulphadimidine and its prognostic significance for treatment with several intermittent isoniazid-containing regimens. Br J Clin Pharmac 1977; 4: 5-14.
13. Chan S L, Yew W W, Ma W K, et al. The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis. Tubercle Lung Dis 1992; 73: 33-38.
14. Sirgel F A, Botha F J H, Parkin D P, et al. The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts. A new method of drug assessment. J Antimicrob Chemother 1993; 32: 867-875.
15. Singapore Tuberculosis Service/British Medical Research Council. Controlled trial of intermittent regimens of rifampin plus isoniazid for pulmonary tuberculosis in Singapore. The results up to 30 months. Am Rev Respir Dis 1977; 116: 807-820.
16. Mitchison D A. Modern methods for assessing the drugs used in the chemotherapy of mycobacterial disease. J Applied Bact 1996; 61: 72S-80S.
17. Mitchison D A. The Garrod Lecture. Understanding the chemotherapy of tuberculosis - current problems. J Antimicrob Chemother 1992; 29: 477-493.
18. Dickinson J M, Mitchison D A. Efficacy of intermittent pyrazinamide in experimental murine tuberculosis. Tubercle 1991; 72: 110-114.
19. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2, 4 and 6 months of pyrazinarnide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Am Rev Respir Dis 1991; 143: 700-706.
20. Dickinson J M, Mitchison D A. Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Am Rev Respir Dis 1981; 123: 367-371.